2/8
07:15 pm
rxrx
Assessing Recursion Pharmaceuticals (RXRX) Valuation As Shares Trade Below Fair Value Estimate [Yahoo! Finance]
Neutral
Report
Assessing Recursion Pharmaceuticals (RXRX) Valuation As Shares Trade Below Fair Value Estimate [Yahoo! Finance]
1/29
07:29 pm
rxrx
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors [Yahoo! Finance]
1/29
09:54 am
rxrx
AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift [Globe and Mail, The (Toronto, Canada)]
Low
Report
AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift [Globe and Mail, The (Toronto, Canada)]
1/29
09:25 am
rxrx
AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift
Low
Report
AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift
1/24
07:11 pm
rxrx
Is Recursion Pharmaceuticals Inc. (RXRX) The Best Overlooked Penny Stock to Invest In? [Yahoo! Finance]
Low
Report
Is Recursion Pharmaceuticals Inc. (RXRX) The Best Overlooked Penny Stock to Invest In? [Yahoo! Finance]
1/20
10:26 am
rxrx
Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory [Yahoo! Finance]
1/18
12:41 pm
rxrx
JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects [Yahoo! Finance]
Medium
Report
JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects [Yahoo! Finance]
1/16
10:38 pm
rxrx
Is Recursion Pharmaceuticals (RXRX) Pricing In Its AI Drug Discovery Ambitions? [Yahoo! Finance]
Medium
Report
Is Recursion Pharmaceuticals (RXRX) Pricing In Its AI Drug Discovery Ambitions? [Yahoo! Finance]
1/15
08:09 pm
rxrx
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]
1/9
06:11 am
rxrx
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know [Yahoo! Finance]
1/7
08:31 pm
rxrx
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates [Yahoo! Finance]
1/7
03:41 pm
rxrx
Lux Capital lands $1.5 billion for its largest fund ever [Yahoo! Finance]
Low
Report
Lux Capital lands $1.5 billion for its largest fund ever [Yahoo! Finance]
1/7
03:18 pm
rxrx
Lux Capital lands $1.5 billion for its largest fund ever [TechCrunch]
Low
Report
Lux Capital lands $1.5 billion for its largest fund ever [TechCrunch]
1/6
07:59 am
rxrx
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference
1/2
09:29 am
rxrx
JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline [Yahoo! Finance]
Low
Report
JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline [Yahoo! Finance]
1/1
08:00 am
rxrx
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. [Yahoo! Finance]
Low
Report
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. [Yahoo! Finance]
1/1
07:15 am
rxrx
Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) [Yahoo! Finance]
Low
Report
Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) [Yahoo! Finance]
12/29
12:11 pm
rxrx
Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP [Yahoo! Finance]
Neutral
Report
Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP [Yahoo! Finance]
12/28
12:57 pm
rxrx
Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform [Yahoo! Finance]
12/24
12:08 pm
rxrx
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? [Yahoo! Finance]
Low
Report
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? [Yahoo! Finance]
12/22
10:34 am
rxrx
How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation [Yahoo! Finance]
Low
Report
How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation [Yahoo! Finance]
12/21
05:16 pm
rxrx
Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades [Yahoo! Finance]
12/21
07:51 am
rxrx
Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? [Yahoo! Finance]
Low
Report
Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? [Yahoo! Finance]
12/18
11:39 am
rxrx
Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 [Seeking Alpha]
Medium
Report
Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 [Seeking Alpha]
12/17
08:45 am
rxrx
Recursion Pharmaceuticals (NASDAQ:RXRX) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $11.00 price target on the stock, up previously from $10.00.
Medium
Report
Recursion Pharmaceuticals (NASDAQ:RXRX) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $11.00 price target on the stock, up previously from $10.00.